


*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**SINO BIOPHARMACEUTICAL LIMITED**  
**中國生物製藥有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

*Website: [www.sinobiopharm.com](http://www.sinobiopharm.com)*

**(Stock code: 1177)**

**VOLUNTARY ANNOUNCEMENT**  
**APPROVAL FOR MARKETING OF “IOPROMIDE INJECTION”**

The board of directors (the “**Board**”) of the Sino Biopharmaceutical Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) announced that the Iopromide Injection (trademark name: Duodian (多碘)), a medical imaging product developed by the Group, has received the approval for marketing from the National Medical Products Administration of China as a diagnostic agent for intravascular and intracorporeal imaging.

Iopromide is a tri-iodinated, non-ionic, water-soluble X-ray contrast agent with high iodine content and good contrast, which is mostly used for electronic computed tomography (CT) enhancement, arteriography and venography, endoscopic retrograde cholangiopancreatography (ERCP), arthrography and other body cavity examinations.

Iodopromide is stable, easy to use, with better systemic tolerance than ionic contrast agents, no genotoxicity or tumorigenic risk, and good tolerance to blood vessels, paravascular tissues, subarachnoid space, or mucous membranes of the human body. Due to its superior water solubility, low osmotic pressure, good tolerance, high safety and low toxic side effects, iodopromide has become a widely used iodine contrast agent with great potential in clinical practice.

Accompanied by the in-depth promotion of Universal Health Coverage and the wide application of medical imaging technology, the demand for contrast agents in China is high and the market prospect is broad. In 2022, the scale of China’s contrast agents market amounted to over RMB10 billion<sup>1)</sup>. At present, only one generic of iopromide injection has been approved in China, which has not met the large clinical demand.

The approval of Duodian will provide more options for the use of iodine contrast agents in clinical medical imaging in China. In addition to Duodian, the Group also has other approved contrast agent products such as gadoxetic acid disodium (trademark name: Xianai(顯愛)) and iodixanol (trademark name: Shabeian (沙貝安)), as well as a number of other contrast agents under research and development. With the launch of more contrast agent products, the Group is poised for new developments in the medical imaging field for the benefit of more patients.

*Source:*

1) Menet

By order of the Board  
**Sino Biopharmaceutical Limited**  
**Tse, Theresa Y Y**  
*Chairwoman*

Hong Kong, 25 March 2024

*As at the date of this announcement, the Board of the Company comprises seven executive directors, namely Ms. Tse, Theresa Y Y, Mr. Tse Ping, Ms. Cheng Cheung Ling, Mr. Tse, Eric S Y, Mr. Tse Hsin, Mr. Tian Zhoushan and Ms. Li Mingqin and five independent non-executive directors, namely Mr. Lu Zhengfei, Mr. Li Dakui, Ms. Lu Hong, Mr. Zhang Lu Fu and Dr. Li Kwok Tung Donald.*